- |||||||||| NY-ESO-1 TCR-T cell therapy / Gilead
Phase I TCR Trial Experience Targeting HPV-16-Driven Tumors () - Jun 15, 2023 - Abstract #IOSUMMITEUROPE2023IO_SUMMIT_EUROPE_157;
However, durable responses are still elusive. Recent translational data point to various mechanisms of treatment resistance employed by the tumor in context of TCR-engineered T cell therapy.
- |||||||||| NY-ESO-1 TCR-T cell therapy / Gilead
Trial completion date, PD(L)-1 Biomarker: NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) (clinicaltrials.gov) - Oct 12, 2020
P1, N=3, Terminated,
Recent translational data point to various mechanisms of treatment resistance employed by the tumor in context of TCR-engineered T cell therapy. Trial completion date: Feb 2020 --> Oct 2020
- |||||||||| NY-ESO-1 TCR-T cell therapy / Gilead
Trial completion date, Trial termination, Trial primary completion date, PD(L)-1 Biomarker: NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) (clinicaltrials.gov) - May 7, 2020
P1, N=3, Terminated,
Trial completion date: Feb 2020 --> Oct 2020 Trial completion date: Jan 2033 --> Feb 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2033 --> Feb 2020; Sponsor has terminated trial to pursue other targets.
- |||||||||| NY-ESO-1 TCR-T cell therapy / Gilead
Enrollment closed, Enrollment change, PD(L)-1 Biomarker: NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) (clinicaltrials.gov) - Jan 6, 2020
P1, N=3, Active, not recruiting,
Trial completion date: Jan 2033 --> Feb 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2033 --> Feb 2020; Sponsor has terminated trial to pursue other targets. Recruiting --> Active, not recruiting | N=18 --> 3
|
